Literature DB >> 28304204

Changes in contrast transit times on digital subtraction angiography post-Pipeline Embolization Device deployment.

Ahmed E Hussein1, Andreas Linninger1,2, Sophia F Shakur1, Fady T Charbel1, Chih-Yang Hsu2, Fady T Charbel1, Ali Alaraj1,2.   

Abstract

It is postulated that hemodynamic changes occur in the distal vascular bed post-deployment of Pipeline Embolization Devices (PEDs). In this paper, we evaluate changes in the contrast transit times (TTs) on digital subtraction angiography (DSA) post-PED interventions. DSA films were analyzed using custom-made software for the time-density relationship at baseline and compared to post-PED deployment. All analyses were performed within the middle cerebral artery (MCA) M1 segment. Analyses included TT10%-100% (time needed for the contrast to change from 10% image intensity to 100%), TT100%-10%, and TT25%-25%. Forty-four patients were included. We found a significant decrease in TT10%-100% (2.79 to 2.24 seconds, p < 0.001) post-PED. There was a significant correlation between the percentage change in TT100%-10% and aneurysm size ( p = 0.02). There was also a significant decrease in TT25%-25% (7.07 to 6.41 seconds, p = 0.02) post-PED. Moreover, there was a significant correlation between the absolute or percentage changes in TT25%-25% and aneurysm size (rho = 0.54, p = 0.05 and rho = 0.29, p = 0.05, respectively). Statistically significant distal intracranial hemodynamic changes occur post-PED deployment. These hemodynamic changes appear to be more pronounced with large and giant aneurysms.

Entities:  

Keywords:  Angiography; Pipeline Embolization Device; cerebral aneurysm; contrast; flow diversion; intracranial hemodynamics; transit time

Mesh:

Substances:

Year:  2017        PMID: 28304204      PMCID: PMC5433610          DOI: 10.1177/1591019916685892

Source DB:  PubMed          Journal:  Interv Neuroradiol        ISSN: 1591-0199            Impact factor:   1.610


  16 in total

1.  Flow analysis with digital subtraction angiography: 2. Acquisition and accuracy of transit-flow measurements.

Authors:  J R Hesselink; K H Chang; K J Chung; L Abbate; M Goodsitt
Journal:  AJNR Am J Neuroradiol       Date:  1986 May-Jun       Impact factor: 3.825

2.  Pipeline for uncoilable or failed aneurysms: results from a multicenter clinical trial.

Authors:  Tibor Becske; David F Kallmes; Isil Saatci; Cameron G McDougall; István Szikora; Giuseppe Lanzino; Christopher J Moran; Henry H Woo; Demetrius K Lopes; Aaron L Berez; Daniel J Cher; Adnan H Siddiqui; Elad I Levy; Felipe C Albuquerque; David J Fiorella; Zsolt Berentei; Miklós Marosfoi; Saruhan H Cekirge; Peter K Nelson
Journal:  Radiology       Date:  2013-02-15       Impact factor: 11.105

3.  Histopathological assessment of fatal ipsilateral intraparenchymal hemorrhages after the treatment of supraclinoid aneurysms with the Pipeline Embolization Device.

Authors:  Yin C Hu; Vivek R Deshmukh; Felipe C Albuquerque; David Fiorella; Randal R Nixon; Donald V Heck; Stanley L Barnwell; Cameron G McDougall
Journal:  J Neurosurg       Date:  2013-12-10       Impact factor: 5.115

Review 4.  Endovascular treatment of intracranial aneurysms with flow diverters: a meta-analysis.

Authors:  Waleed Brinjikji; Mohammad H Murad; Giuseppe Lanzino; Harry J Cloft; David F Kallmes
Journal:  Stroke       Date:  2013-01-15       Impact factor: 7.914

5.  Incidence of delayed ipsilateral intraparenchymal hemorrhage after stent-assisted coiling of intracranial aneurysms in a high-volume single center.

Authors:  Yasha Kayan; Josser E Delgado Almandoz; Jennifer L Fease; Kira Tran; Anna M Milner; Jill M Scholz
Journal:  Neuroradiology       Date:  2015-11-28       Impact factor: 2.804

6.  Risk Factors for Hemorrhagic Complications following Pipeline Embolization Device Treatment of Intracranial Aneurysms: Results from the International Retrospective Study of the Pipeline Embolization Device.

Authors:  W Brinjikji; G Lanzino; H J Cloft; A H Siddiqui; D F Kallmes
Journal:  AJNR Am J Neuroradiol       Date:  2015-08-06       Impact factor: 3.825

7.  Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.

Authors:  Hans-Christoph Diener; Julien Bogousslavsky; Lawrence M Brass; Claudio Cimminiello; Laszlo Csiba; Markku Kaste; Didier Leys; Jordi Matias-Guiu; Hans-Jürgen Rupprecht
Journal:  Lancet       Date:  2004 Jul 24-30       Impact factor: 79.321

8.  Correlation between angiographic transit times and neurological status on admission in patients with aneurysmal subarachnoid hemorrhage.

Authors:  Alexander Ivanov; Andreas Linninger; Chih-Yang Hsu; Sepideh Amin-Hanjani; Victor A Aletich; Fady T Charbel; Ali Alaraj
Journal:  J Neurosurg       Date:  2015-10-09       Impact factor: 5.115

9.  Cerebral hyperperfusion after flow diversion of large intracranial aneurysms.

Authors:  Albert Ho Yuen Chiu; Jason Wenderoth
Journal:  J Neurointerv Surg       Date:  2012-11-27       Impact factor: 5.836

Review 10.  Delayed hemorrhagic complications after flow diversion for intracranial aneurysms: a literature overview.

Authors:  Aymeric Rouchaud; Waleed Brinjikji; Giuseppe Lanzino; Harry J Cloft; Ramanathan Kadirvel; David F Kallmes
Journal:  Neuroradiology       Date:  2015-11-09       Impact factor: 2.804

View more
  2 in total

1.  2D parametric contrast time-density analysis for the prediction of complete aneurysm occlusion at six months' post-flow diversion stent.

Authors:  Ahmed E Hussein; Meghana Shownkeen; Andre Thomas; Christopher Stapleton; Denise Brunozzi; Jessica Nelson; John Naumgart; Andreas Linninger; Gursant Atwal; Ali Alaraj
Journal:  Interv Neuroradiol       Date:  2020-02-26       Impact factor: 1.610

2.  Intracranial contrast transit times on digital subtraction angiography decrease more in patients with delayed intraparenchymal hemorrhage after Pipeline.

Authors:  Denise Brunozzi; Sophia F Shakur; Fady T Charbel; Ali Alaraj
Journal:  Interv Neuroradiol       Date:  2017-12-12       Impact factor: 1.610

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.